Canine urinary tract infections: a comparison of in vitro antimicrobial susceptibility test results and response to oral therapy with ampicillin or with trimethoprim-sulfa.
In vitro susceptibility testing correctly predicted the outcome of ampicillin therapy in all 56 urinary tract infections (UTI) caused by coagulase-positive staphylococci (Staphylococcus aureus and S intermedius), in all 26 UTI caused by Proteus mirabilis, in 38 of 44 UTI caused by Escherichia coli, in 29 of 31 UTI caused by Streptococcus spp, in 8 of 10 UTI caused by Klebsiella pneumoniae, and in 16 of 20 UTI caused by other bacterial species. Thus, 173 of 187 (92.5%) isolates responded to ampicillin therapy in a manner predicted by in vitro susceptibility test results. In vitro susceptibility testing correctly predicted the outcome of therapy with trimethoprim-sulfa in 119 of 138 UTI caused by Escherichia coli, in 33 of 45 UTI caused by Klebsiella pneumoniae, in 38 of 43 UTI caused by Proteus mirabilis, in 21 of 25 UTI caused by Streptococcus spp, in 9 of 11 UTI caused by coagulase-positive staphylococci, and in 19 of 21 UTI caused by other bacterial species. Thus, 239 of 283 (84%) isolates responded to trimethoprim-sulfa therapy in a manner predicted by in vitro susceptibility test results.
D000667:Ampicillin / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000892:Anti-Infective Agents, Urinary / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects*; D001424:Bacterial Infections / Q000188:drug therapy / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004338:Drug Combinations / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D008297:Male; D008826:Microbial Sensitivity Tests; D011379:Prognosis; D013045:Species Specificity; D013411:Sulfadiazine / Q000494:pharmacology / Q000627:therapeutic use*; D013420:Sulfamethoxazole / Q000494:pharmacology / Q000627:therapeutic use*; D014295:Trimethoprim / Q000494:pharmacology / Q000627:therapeutic use*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000662:veterinary*; D000096926:Benzenesulfonamides
D000667:Ampicillin; D000900:Anti-Bacterial Agents; D000892:Anti-Infective Agents, Urinary; D004338:Drug Combinations; D013411:Sulfadiazine; D013420:Sulfamethoxazole; D014295:Trimethoprim; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; C024873:sulfadiazine, trimethoprim drug combination; D000096926:Benzenesulfonamides